首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1917890

個人化醫療市場－2026-2031年預測

Personalized Medicine Market - Forecast from 2026 to 2031

出版日期: 2026年01月08日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計個人化醫療市場將從 2025 年的 4,636.8 億美元成長到 2031 年的 7,673.8 億美元，複合年成長率為 8.76%。

個人化醫療市場代表著醫療保健領域的一次根本性轉變，它摒棄了「一刀切」的模式，轉而採用以數據為導向的精準診斷、治療和預防方法。這種模式整合了基因、分子、環境和生活方式訊息，從而根據每位患者的獨特特徵量身定做醫療決策和干涉措施。在多種技術整合的推動下，該市場正透過改善治療效果、減少不利事件和最佳化醫療資源，徹底改變從腫瘤學到心臟病學的各個治療領域。基因組學的突破、診斷能力的提升以及製藥和診斷行業的策略調整，是推動其成長的主要動力。

該市場的核心技術驅動力是基因組學和多體學技術的持續進步。蛋白質體學、代謝體學和轉錄組學的成熟，以及基因測序成本和時間的快速下降，為表徵個體分子特徵提供了前所未有的能力。這種深入的生物學洞察能夠識別特定的生物標記（例如基因突變、蛋白質表現和代謝特徵），從而預測疾病感受性、預後和治療反應。基於這些分子促進因素的患者分層是精準醫療的基礎原則，它推動了標靶治療和診斷方法的開發與應用。

推動臨床應用的重要因素之一是藥物基因體學的發展。藥物基因體學研究個別基因組成對藥物反應的影響。透過識別影響藥物代謝、療效和毒性的基因變異，臨床醫生可以在治療開始前最佳化藥物選擇和劑量。這種方法已被證實能夠顯著減少處方中的試驗誤過程，降低藥物不良反應的發生率，並改善治療效果。隨著其臨床效用和成本效益的證據不斷積累，藥物基因組學正日益融入標準治療方案和藥物研發流程，鞏固其在個人化醫療生態系統中的地位。

隨著治療方法的進步，個人化診斷和伴隨診斷也不斷發展並日益成熟。市場正從單基因檢測向複雜的多重分析檢測和能夠同時分析數百個基因組標靶的次世代定序平台轉型。伴隨診斷，即與特定治療產品使用直接相關的檢測，如今已成為許多標靶癌症療法獲得監管和商業認可的先決條件。這些診斷技術的開發對於識別最有可能從特定藥物中獲益的患者亞群至關重要，從而確保治療惠及合適的患者，最大限度地提高臨床獲益，並提升高成本特藥的價值提案。

競爭與合作並存是該市場的顯著特徵。成功的個人化醫療需要傳統上各自獨立的學科之間進行深度整合。這促使製藥公司、診斷開發商、技術/平台提供者和數據分析公司之間建立了大量的策略聯盟和夥伴關係。製藥公司利用這些合作，從藥物發現和開發的早期階段就將生物標記策略納入其中，而診斷公司則能夠接觸到治療管線和臨床檢驗路徑。這些協同效應使得研究成果能夠快速轉化為臨床可操作的工具和治療方法，從而縮短開發週期，並提高獲得監管和商業成功的可能性。

從地理上看，北美保持著主導地位，這得益於多種因素的共同作用，包括強大的生物技術和製藥行業、公共和私人對基因組研究的大量投資、相對有利的新型診斷和標靶治療法規環境，以及支持先進檢測的高額醫療保健支出。該地區完善的臨床試驗基礎設施，加上日益重視以價值為導向的醫療保健模式（該模式獎勵治療效果的改善），進一步鞏固了其作為個性化醫療創新主導培養箱和早期採用者的地位。

這個市場涵蓋了廣泛的價值鏈，從支援分析的技術平台（例如次世代定序儀和高通量儀器）到診斷測試開發商、解讀複雜數據的生物資訊公司，再到開發客製化標靶治療的治療開發商。主要產業參與者在這條價值鏈的多個環節中競爭與合作，而定序技術領導企業則提供支撐整個產業發展的關鍵工具。

總之，個人化醫療市場正從一個充滿前景的概念發展成為現代生物醫學研究和臨床照護的核心組織原則。其成長軌跡與生物學知識的持續擴展、運算能力的不斷提升以及資料整合能力的不斷發展密不可分。未來的發展將受到許多挑戰的影響，例如檢測標準化、為複雜診斷建立清晰的報銷機制、臨床醫生教育的需求以及基因數據的倫理管理。然而，憑藉其改善患者預後的顯著能力以及更有效地指導高成本治療的經濟必要性，個人化醫療必將繼續重新定義不斷擴展的頻譜的護理標準，使醫療保健更具預測性、預防性和精準性。

本報告的主要優勢：

深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢，以及它們將如何塑造未來的市場發展。
可操作的建議：利用這些見解，在動態環境中製定策略決策，發展新的業務流和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

您打算如何使用這份報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 按類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 按類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 按類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 德國
  - 法國
  - 英國
  - 西班牙
  - 義大利
  - 其他
中東和非洲
- 按類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 其他
亞太地區
- 按類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 中國
  - 印度
  - 日本
  - 韓國
  - 印尼
  - 泰國
  - 台灣
  - 其他

第9章：競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
競爭對手儀錶板

第10章：公司簡介

F. Hoffmann-La Roche Ltd.
Illumina, Inc.
Novartis Ag
Pfizer Inc.
Merck KgaA
Astrazeneca Plc
Bristol Myers Squibb Company
Amgen Inc.
Guardant Health Inc
Caris Life Sciences
Thermo Fisher Scientific Inc.

第11章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061615955

Personalized Medicine Market, with a 8.76% CAGR, is anticipated to reach USD 767.383 billion in 2031 from USD 463.680 billion in 2025.

The personalized medicine market represents a fundamental shift in healthcare, moving away from a one-size-fits-all model towards a targeted, data-driven approach to diagnosis, treatment, and prevention. This paradigm tailors medical decisions and interventions to the individual characteristics of each patient, integrating genetic, molecular, environmental, and lifestyle information. Enabled by converging technological advancements, the market is revolutionizing therapeutic areas from oncology to cardiology by improving treatment efficacy, minimizing adverse events, and optimizing healthcare resource utilization. Its growth is propelled by breakthroughs in genomic science, the expansion of diagnostic capabilities, and strategic realignments across the pharmaceutical and diagnostic industries.

The core technological driver of this market is the continuous advancement in genomics and multi-omics technologies. The precipitous decline in the cost and time of genomic sequencing, coupled with the maturation of proteomics, metabolomics, and transcriptomics, has unlocked unprecedented ability to characterize an individual's molecular profile. This deep biological insight allows for the identification of specific biomarkers-genetic mutations, protein expressions, or metabolic signatures-that can predict disease susceptibility, prognosis, and response to therapy. The ability to stratify patients based on these molecular drivers is the foundational principle of personalized medicine, enabling the development and application of targeted therapeutics and diagnostics.

A critical application driving clinical adoption is the growth of pharmacogenomics-the study of how an individual's genetic makeup affects their response to drugs. By identifying genetic variants that influence drug metabolism, efficacy, and toxicity, clinicians can optimize medication selection and dosing before treatment begins. This approach demonstrably reduces the trial-and-error process in prescribing, decreases the incidence of adverse drug reactions, and improves therapeutic outcomes. As evidence of its clinical utility and cost-effectiveness accumulates, pharmacogenomics is becoming increasingly integrated into standard care pathways and drug development processes, solidifying its role within the personalized medicine ecosystem.

Parallel to therapeutic advances is the expansion and sophistication of personalized diagnostics and companion diagnostics. The market is moving beyond single-gene tests to complex multi-analyte assays and next-generation sequencing panels that can interrogate hundreds of genomic targets simultaneously. Companion diagnostics, which are tests specifically linked to the use of a corresponding therapeutic product, are now a regulatory and commercial prerequisite for many targeted cancer therapies. The development of these diagnostics is essential for identifying the patient subpopulation most likely to benefit from a specific drug, thereby ensuring treatment is delivered to the right patient, maximizing clinical benefit and supporting the value proposition of high-cost specialty pharmaceuticals.

The competitive and collaborative landscape is a defining feature of the market. Success in personalized medicine requires deep integration across traditionally separate domains. This has led to a surge in strategic collaborations and partnerships between pharmaceutical companies, diagnostic developers, technology/platform providers, and data analytics firms. Pharmaceutical companies leverage these alliances to embed biomarker strategies early in drug development, while diagnostic companies gain access to therapeutic pipelines and clinical validation pathways. These synergies are accelerating the translation of research into clinically actionable tools and treatments, reducing development timelines and improving the probability of regulatory and commercial success.

Geographically, North America maintains a leading position, driven by a confluence of factors. These include a robust biotechnology and pharmaceutical sector, substantial public and private investment in genomic research, a relatively favorable regulatory environment for novel diagnostics and targeted therapies, and high healthcare expenditure that can support advanced testing. The region's well-established infrastructure for clinical trials and a growing emphasis on value-based care models that reward improved outcomes further reinforce its role as the primary incubator and early adopter of personalized medicine innovations.

The market encompasses a broad value chain, from the technology platforms enabling analysis-such as next-generation sequencers and high-throughput instrumentation-to the diagnostic test developers, bioinformatics companies interpreting complex data, and the therapeutic developers creating matched targeted drugs. Key industry players often compete and collaborate across multiple points in this chain, with leaders in sequencing technology providing the essential tools that enable the entire field.

In conclusion, the personalized medicine market is transitioning from a promising concept to a central organizing principle of modern biomedical research and clinical care. Its growth trajectory is inextricably linked to the ongoing expansion of biological knowledge, computational power, and data integration capabilities. Future development will be shaped by challenges including the standardization of testing, the establishment of clear reimbursement pathways for complex diagnostics, the need for clinician education, and the ethical management of genetic data. However, the demonstrated ability to improve patient outcomes and the economic imperative to direct costly therapies more efficiently ensure that personalized medicine will continue to redefine standards of care across a growing spectrum of diseases, making healthcare more predictive, preventive, and precise.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Personalized Medicine Market Segmentation

By Type
Pharmacogenomics
Biomarkers
Precision Therapeutics
Others
By Application
Oncology
Cardiology
Infectious Disease
Neurology
Others
By End-User
Hospitals & Clinics
Diagnostics Centers
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Italy
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Taiwan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. PERSONALIZED MEDICINE MARKET BY TYPE

5.1. Introduction
5.2. Pharmacogenomics
5.3. Biomarkers
5.4. Precision Therapeutics
5.5. Others

6. PERSONALIZED MEDICINE MARKET BY APPLICATION

6.1. Introduction
6.2. Oncology
6.3. Cardiology
6.4. Infectious Disease
6.5. Neurology
6.6. Others

7. PERSONALIZED MEDICINE MARKET BY END-USER

7.1. Introduction
7.2. Hospitals & Clinics
7.3. Diagnostics Centers
7.4. Others

8. PERSONALIZED MEDICINE MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By End-User
- 8.2.4. By Country
  - 8.2.4.1. USA
  - 8.2.4.2. Canada
  - 8.2.4.3. Mexico
8.3. South America
- 8.3.1. By Type
- 8.3.2. By Application
- 8.3.3. By End-User
- 8.3.4. By Country
  - 8.3.4.1. Brazil
  - 8.3.4.2. Argentina
  - 8.3.4.3. Others
8.4. Europe
- 8.4.1. By Type
- 8.4.2. By Application
- 8.4.3. By End-User
- 8.4.4. By Country
  - 8.4.4.1. Germany
  - 8.4.4.2. France
  - 8.4.4.3. United Kingdom
  - 8.4.4.4. Spain
  - 8.4.4.5. Italy
  - 8.4.4.6. Others
8.5. Middle East and Africa
- 8.5.1. By Type
- 8.5.2. By Application
- 8.5.3. By End-User
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
  - 8.5.4.2. UAE
  - 8.5.4.3. Others
8.6. Asia Pacific
- 8.6.1. By Type
- 8.6.2. By Application
- 8.6.3. By End-User
- 8.6.4. By Country
  - 8.6.4.1. China
  - 8.6.4.2. India
  - 8.6.4.3. Japan
  - 8.6.4.4. South Korea
  - 8.6.4.5. Indonesia
  - 8.6.4.6. Thailand
  - 8.6.4.7. Taiwan
  - 8.6.4.8. Others